Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response.
Adult
Humans
Male
Female
Carcinoma, Hepatocellular
/ etiology
Liver Neoplasms
/ epidemiology
Risk Factors
Prospective Studies
Retrospective Studies
Hepatitis C
/ complications
Liver Cirrhosis
/ complications
Sustained Virologic Response
Hepacivirus
Antiviral Agents
/ therapeutic use
Hepatitis C, Chronic
/ complications
external validation
hepatitis C
hepatocellular carcinoma
risk prediction
sustained virological response
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
22
02
2023
received:
31
10
2022
accepted:
03
03
2023
medline:
18
5
2023
pubmed:
10
3
2023
entrez:
9
3
2023
Statut:
ppublish
Résumé
Hepatitis C patients with advanced fibrosis or cirrhosis are at high risk of developing hepatocellular carcinoma (HCC) even after sustained virological response (SVR). Several HCC risk scores have been developed but which one is most suitable for this population is unclear. In this study, we compared the prediction ability of the aMAP model, THRI model, PAGE-B model and Models of HCV in a prospective hepatitis C cohort in order to propose better model(s) to clinical practice. Adult hepatitis C patients with baseline advanced fibrosis (141 cases), compensated cirrhosis (330 cases) and decompensated cirrhosis (80 cases) were included and followed up every 6 months for about 7 years or until HCC development. Demographic data, medical history and laboratory results were recorded. HCCs were diagnosed by radiography, AFP or liver histology. The median follow-up period was 69.93(60.99-74.93) months, during which 53 (9.62%) patients developed HCC. The areas under the receiver operating characteristic curve of aMAP, THRI, PAGE-B and Models of HCV scores were 0.74, 0.72, 0.70 and 0.63 respectively. The predictive power of the aMAP model score was comparable to that of THRI, PAGE-Band higher than that of Models of HCV (p < 0.05). Dividing patients into non-high-risk and high-risk groups, the cumulative incidence rates of HCC based on aMAP, THRI, PAGE-B and Models of HCV was 5.57% vs. 24.17%, 1.10% vs. 13.90%, 5.80% vs. 15.90% and 6.41% vs. 13.81% (all p < 0.05). The AUC of the four models were all below 0.7 in male while all were higher than 0.7 in female. The performance of all the models was not influenced by fibrosis stage. aMAP, THRI model and PAGE-B model were all performed well while THRI model and PAGE-B model were easier to calculate. There was no need to select score according to fibrosis stage but should be caution when explain the results in male patients.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
559-566Informations de copyright
© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
Références
Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45(3):101596. doi:10.1016/j.clinre.2020.101596 Epub 2021 Feb 17. PMID: 33610022.
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, el-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996-1005. doi:10.1053/j.gastro.2017.06.012 Epub 2017 Jun 19. PMID: 28642197.
Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;S0168-8278(17):32273-0. doi:10.1016/j.jhep.2017.08.030 Epub ahead of print. PMID: 28887168; PMCID: PMC5837901.
Muzica CM, Stanciu C, Huiban L, et al. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: a debate near the end. World J Gastroenterol. 2020;26(43):6770-6781. doi:10.3748/wjg.v26.i43.6770 PMID: 33268960; PMCID: PMC7684455.
European Association for the Study of the liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461-511. doi:10.1016/j.jhep.2018.03.026 Epub 2018 Apr 9. PMID: 29650333.
Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686-721. doi:10.1002/hep.31060 PMID: 31816111.
Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73(6):1368-1378. doi:10.1016/j.jhep.2020.07.025 Epub 2020 Jul 21. PMID: 32707225.
Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. 2017;S0168-8278(17):32248-1. doi:10.1016/j.jhep.2017.07.033 Epub ahead of print. PMID: 28844936.
Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800-806. doi:10.1016/j.jhep.2015.11.035 Epub 2015 Dec 8. PMID: 26678008.
Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018;69(5):1088-1098. doi:10.1016/j.jhep.2018.07.024 Epub 2018 Aug 21. PMID: 30138686; PMCID: PMC6201746.
Azzi J, Dorival C, Cagnot C, et al. Prediction of hepatocellular carcinoma in hepatitis C patients with advanced fibrosis after sustained virologic response. Clin Res Hepatol Gastroenterol. 2022;46(6):101923. doi:10.1016/j.clinre.2022.101923 Epub 2022 Apr 9. PMID: 35405354.
Alonso López S, Manzano ML, Gea F, et al. A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis. Hepatology. 2020;72(6):1924-1934. doi:10.1002/hep.31588 Epub 2020 Nov 10. PMID: 33022803.
Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264-1278. doi:10.1053/j.gastro.2019.07.033 Epub 2019 Jul 26. PMID: 31356807; PMCID: PMC6815714.
Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-370. doi:10.1007/s12072-017-9799-9 Epub 2017 Jun 15. PMID: 28620797; PMCID: PMC5491694.
El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology. 2016;64(1):130-137. doi:10.1002/hep.28535 Epub 2016 Apr 19. Erratum in: Hepatology. 2016 Sep;64(3):1010. PMID: 26946190; PMCID: PMC4917456.
Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66(3):504-513. doi:10.1016/j.jhep.2016.10.028 Epub 2016 Nov 4. PMID: 27818234.
Brown JL. Interferon therapy reduces the risk for hepatocellular carcinoma. Gut. 2000;47(5):610-1. doi:10.1136/gut.47.5.610
Sacco M, Saracco GM. The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C. Minerva Gastroenterol (Torino). 2021;67(3):264-272. doi:10.23736/S2724-5985.21.02835-X Epub 2021 Apr 15. PMID: 33856147.
Nahon P, Layese R, Bourcier V, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155(5):1436-1450.e6. doi:10.1053/j.gastro.2018.07.015 Epub 2018 Jul 19. PMID: 30031138.
Degasperi E, Galmozzi E, Pelusi S, et al. Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs. Hepatology. 2020;72(6):1912-1923. doi:10.1002/hep.31500 Epub 2020 Nov 20. PMID: 32762045.
Gui H, Huang Y, Zhao G, et al. External validation of aMAP hepatocellular carcinoma risk score in patients with chronic hepatitis B-related cirrhosis receiving ETV or TDF therapy. Front Med (Lausanne). 2021;8:677920. doi:10.3389/fmed.2021.677920 PMID: 34422855; PMCID: PMC8371628.
Ferreira da Silva AC, Cunha-Silva M, Sevá-Pereira T, Mazo DF. Evaluation of the hepatocellular carcinoma predictive scores PAGE-B and mPAGE-B among Brazilian patients with chronic hepatitis B virus infection. Viruses. 2022;14(9):1968. doi:10.3390/v14091968 PMID: 36146774; PMCID: PMC9503912.
Yamashita Y, Joshita S, Sugiura A, et al. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. Hepatol Res. 2021;51(9):933-942. doi:10.1111/hepr.13689 Epub 2021 Jul 12. PMID: 34216422.
Zhang H, Zhu J, Xi L, Xu C, Wu A. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study. World J Surg Oncol. 2019;17(1):75. doi:10.1186/s12957-019-1619-3 PMID: 31039803; PMCID: PMC6492382.